slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 5,551-5,580
Pages 395
Rows per page 30
Slide function
5,551-5,580 of 11,828
13
Includes PET scan imagery showing metabolic response in a patient.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Traction1 hit
15
Data presented at AACR 2021. Shows two separate mouse model experiments (H1975-OsiR and H1975).Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a Kaplan-Meier survival plot to illustrate therapeutic efficacy.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Traction1 hit
20
The slide presents two charts: a line chart showing tumor progression over time and a bar chart showing tumor intensity at week 4.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a Kaplan-Meier survival plot to demonstrate efficacy. The visual comparison of lung tissue provides qualitative support for the quantitative survival data.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
20
The slide uses TUSC2 as the synonym for REQORSA in the charts. Data shows statistical significance (p-values) for the triple combination.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
24
The slide uses a vertical process flow diagram to illustrate strategic focus areas.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
31
The slide presents a Glucose Tolerance Test line chart and a bar chart for beta cell mass, demonstrating the efficacy of the AAV8-PM gene therapy.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
32
Includes a line chart showing blood glucose over time and a bar chart showing beta cell mass comparison.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
33
The charts track insulin/carb ratios over time relative to a viral infusion event.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
42
The slide uses a two-column layout to contrast past progress with future goals.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Action1 hit
08
The slide uses a callout bubble to emphasize the consistency of findings across all listed models.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
14
The slide uses a process-style arrow diagram to represent the sequence of Phase 1 study components.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
17
The slide presents clinical trial outcomes for a pharmaceutical asset.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
21
The slide uses a network graph to visualize gene interactions, categorized by color-coded functional groups.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
06
Includes pro-forma data and forward-looking projections for 2022-2025.Lanvin | Investor Presentation Deck | 58 slides · Lanvin Group
Pitch deck Investor relations 1 hit
14
The slide uses a combination of bar charts for group/brand growth and big-number metrics for specific segment growth, accompanied by product imagery.Lanvin | Investor Presentation Deck | 58 slides · Lanvin Group
Pitch deck Investor relations Beat · Solution1 hit
16
The slide uses a horizontal timeline format to illustrate corporate growth through M&A.Lanvin | Investor Presentation Deck | 58 slides · Lanvin Group
Pitch deck Investor relations 1 hit
38
Shows strong revenue growth (+73%) alongside stable adjusted EBITDA.Lanvin | Investor Presentation Deck | 58 slides · Lanvin Group
Pitch deck Investor relations Beat · Financials1 hit
08
FA likely refers to Friedreich's Ataxia; FXN refers to frataxin protein.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
11
The slide displays two dot plots with error bars representing median and 25th/75th percentiles for different dose cohorts over time.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
12
The chart displays a longitudinal study of FXN concentration across different dose groups (Placebo, 25mg, 50mg, 100mg) at Baseline, Day 4/7, and Day 13.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
13
The slide uses a two-part structure to address clinical safety and non-clinical toxicology findings.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
21
The slide displays two dot plots with error bars representing median and 25th/75th percentiles.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
22
The slide presents two dot plots with error bars representing median and 25th/75th percentiles for FXN concentration and change from baseline.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
27
The slide uses a two-column list format to contrast cardiac and neurologic study outcomes.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
28
Kaplan-Meier survival curve showing significant separation between treatment and vehicle groups.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
29
The slide uses a bulleted list with checkmarks to summarize key findings from a specific mouse model study.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
30
Data shows functional replacement of hFXN and normalization of gene expression.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
31
Data presented as line charts with error bars, comparing KO: CTI-1601, KO: Vehicle, and Wild-type: Vehicle.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit